Why Is Apellis Pharmaceuticals Up 18.4 percent Since Last Earnings Report?
| APLS Stock | USD 33.21 0.07 0.21% |
Slightly above 54% of Apellis Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Apellis Pharmaceuticals suggests that many traders are impartial. Apellis Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Apellis Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Apellis |
Apellis Pharmaceuticals reported earnings 30 days ago. Whats next for the stock We take a look at earnings estimates for some clues.
Read at finance.yahoo.com
 |
Apellis Pharmaceuticals Fundamental Analysis
We analyze Apellis Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apellis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apellis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Apellis Pharmaceuticals is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Apellis Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Apellis Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Apellis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Apellis Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Apellis Pharmaceuticals Related Equities
| INZY | Inozyme Pharma | 6.41 | ||||
| MDGL | Madrigal Pharmaceuticals | 5.12 | ||||
| AKRO | Akero Therapeutics | 3.31 | ||||
| ABOS | Acumen Pharmaceuticals | 2.78 | ||||
| DAWN | Day One | 2.65 | ||||
| AMLX | Amylyx Pharmaceuticals | 2.27 | ||||
| MREO | Mereo BioPharma | 1.82 | ||||
| BPMC | Blueprint Medicines | 1.36 | ||||
| IMVT | Immunovant | 1.49 | ||||
| TERN | Terns Pharmaceuticals | 3.14 | ||||
| XFOR | X4 Pharmaceuticals | 4.69 |
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.